1063 patents
Page 14 of 54
Utility
Treatment of Renal Cancer Using a Combination of an ANTI-PD-1 Antibody and Another Anti-cancer Agent
8 Dec 22
This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent.
Maria JURE-KUNKEL, Paul GAGNIER, David FELTQUATE
Filed: 4 May 22
Utility
Tumor Necrosis Factor-like Ligand 1A Specific Antibodies and Compositions and Uses Thereof
8 Dec 22
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A).
Robert ARCH, Jun ZHANG, Michelle MADER, Tetsuya ISHINO, Joel BARD, William FINLAY, Orla CUNNINGHAM, Ciara REILLY, Peter BRAMS, Brigitte DEVAUX, Haichun HUANG, Karla HENNING
Filed: 28 Jul 22
Utility
Substituted Heterocyclic Compounds
8 Dec 22
Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman
Filed: 13 May 22
Utility
M-protein Assays and Uses Thereof
8 Dec 22
The disclosure provides methods for measuring M-proteins in a biological sample obtained from a subject, comprising applying purified immunoglobulins to a liquid chromatography (LC) mass spectrometry (MS).
Rasa SANTOCKYTE, Jianing ZENG, Oscar PUIG
Filed: 4 Nov 20
Utility
Immunomodulators
8 Dec 22
In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80.
Tao WANG, Paul Michael SCOLA, Zhongxing ZHANG
Filed: 29 Oct 20
Utility
Cell surface conjugates and related cell compositions and methods
6 Dec 22
Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates.
Lothar Germeroth, Christian Stemberger
Filed: 19 Jan 18
Utility
System for Determining Accuracy of Serially-connected Drug Modules In a Combinatorial Drug Delivery Device Using Voltage
1 Dec 22
A combinatorial drug delivery device is provided herein including: a plurality of serially connectable modules, each including at least one drug component; and, a master controller.
Martin John McLoughlin, Stephen Lawrence Zieminski, Jeffrey Manfred Gunnarsson
Filed: 2 Nov 20
Utility
Solid Forms of 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, Compositions Thereof and Methods of Their Use
1 Dec 22
Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
Marie Georges Beauchamps, Robert Hilgraf, Mohit Atul Kothare, Hon-Wah Man, Mark A. Nagy
Filed: 27 Dec 21
Utility
Combination Therapy with Anti-pvrig Antibodies Formulations and ANTI-PD-1 Antibodies
1 Dec 22
The present invention is directed to combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
Adeboye Henry Adewoye, John Hunter, Anat Cohen-Dayag, Paul A. Basciano, Brian D. Lamon
Filed: 28 Jul 20
Utility
Bicyclic Heteroaryl Compounds Useful As IRAK4 Inhibitors
1 Dec 22
John Hynes, Hong Wu, Venkatram Reddy Paidi, Subba Rao Polimera, Satheesh Kesavan Nair, Joseph B. Santella
Filed: 12 Aug 20
Utility
System for Interrogating Serially-connected Drug Modules In a Combinatorial Drug Delivery Device
1 Dec 22
In one aspect, a combinatorial drug delivery device is provided herein including: a plurality of serially connectable modules, each including at least one drug component; and, a master controller having a computing processing unit.
Martin John McLoughlin, Jeffrey Manfred Gunnarsson
Filed: 2 Nov 20
Utility
1H-INDAZOLE Carboxamides As Receptor-interacting Protein Kinase 1 Inhibitors (RIPK1)
1 Dec 22
Junqing Guo, Jie Chen, Carolyn Diane Dzierba, Amy C. Hart, Guanglin Luo, John E. Macor, Willian J. Pitts, Sing-Yuen Sit
Filed: 12 Sep 19
Utility
Indazole Carboxamides As Kinase Inhibitors
1 Dec 22
Jie Chen, Carolyn Diane Dzierba, Junqing Goo, Amy C. Hart, William J. Pitts, Sing-Yuen Sit
Filed: 2 Oct 20
Utility
Imaging methods using
29 Nov 22
The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
David Donnelly, David K. Leung
Filed: 9 Mar 21
Utility
Fibronectin type III domain proteins with enhanced solubility
29 Nov 22
Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated.
Aaron P. Yamniuk, Stanley R. Krystek
Filed: 21 Aug 20
Utility
ANTI-TREM-1 Antibodies and Uses Thereof
24 Nov 22
Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene.
Achal M. PASHINE, Derek A. HOLMES, Clarence K. ZHANG, Dmitry OSTANIN
Filed: 15 Jul 20
Utility
Alternative Fluidic Pathing for Serially Connectable Drug Modules
24 Nov 22
Various embodiments are disclosed herein related to fluidic connections for modules useable in combinatorial drug delivery devices.
Martin John McLoughlin, Stephen Lawrence Zieminski, Mark Steven Howansky, Frank Berardocco
Filed: 9 Nov 20
Utility
Medication Error Detection System
24 Nov 22
Various embodiments are provided herein for checking proper inclusion and sequencing of drug modules in a combinatorial drug delivery device.
Martin John McLoughlin, Stephen Lawrence Zieminski, Jeffrey Manfred Gunnarsson, Nitin Venkat Vudathala
Filed: 27 Oct 20
Utility
Compounds and compositions for treating conditions associated with sting activity
22 Nov 22
This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human).
Gary Glick, Shomir Ghosh, Edward James Olhava, William R. Roush, Roger Jones
Filed: 28 Jan 21
Utility
Piston Valving for Serially Connectable Drug Modules of a Combinatorial Drug Delivery Device
17 Nov 22
A valving arrangement is provided herein for regulating fluidics of modules usable in a combinatorial drug delivery device.
Martin John McLoughlin, Stephen Lawrence Zieminski, Mark Steven Howansky, Mariano Mumpower, Melanie Marie Springer, Katherine Alina Goetz, Benjamin Richard Lane
Filed: 9 Nov 20